Published in Br J Pharmacol on January 01, 1983
Atenolol reduces plasma melatonin concentration in man. Br J Clin Pharmacol (1983) 1.01
Neuroimmune endocrine effects of antidepressants. Neuropsychiatr Dis Treat (2012) 0.86
Plasma melatonin during desmethylimipramine treatment: evidence for changes in noradrenergic transmission. Br J Clin Pharmacol (1985) 0.79
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
The pineal gland: a neurochemical transducer. Science (1974) 1.78
Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature (1975) 1.45
Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science (1980) 1.43
Action of mianserin and zimelidine on the norepinephrine receptor coupled adenylate cyclase system in brain: subsensitivity without reduction in beta-adrenergic receptor binding. Neuropharmacology (1980) 1.19
Blockade of presynaptic alpha-receptors and of amine uptake in the rat brain by the antidepressant mianserine. Naunyn Schmiedebergs Arch Pharmacol (1977) 1.17
Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J Pharmacol Exp Ther (1978) 1.15
Inhibition of serotonin reuptake. Fed Proc (1977) 1.11
[Profile of pharmacological actions of NAB 365 (clenbuterol), a novel broncholytic agent with selective activity on adrenergic beta2-receptors (author's transl)]. Arzneimittelforschung (1976) 1.05
Circadian and seasonal rhythms in alpha- and beta-adrenergic receptors in the rat brain. Brain Res (1981) 0.99
Circadian cycles in binding of 3H-alprenolol to beta-adrenergic receptor sites in rat pineal. Nature (1975) 0.98
Pineal beta adrenergic receptor: correlation of binding of 3H-l-alprenolol with stimulation of adenylate cyclase. J Pharmacol Exp Ther (1976) 0.98
The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology (1980) 0.97
Melatonin radioimmunoassay. J Clin Endocrinol Metab (1975) 0.95
Electroconvulsive shock treatment decrease beta-adrenergic receptor sensitivity in rat brain. Nature (1979) 0.91
Determination of a dark-induced increase of pineal N-acetyl transferase activity and simultaneous radioimmunoassay of melatonin in pineal, serum and pituitary tissue of the male rat. J Endocrinol (1977) 0.90
Control of pineal indole biosynthesis by changes in sympathetic tone caused by factors other than environmental lighting. Proc Natl Acad Sci U S A (1973) 0.90
Effect of iprindole on norepinephrine turnover and transport. Psychopharmacologia (1974) 0.88
Adrenergic and serotonergic receptor binding in rat brain after chronic desmethylimipramine treatment. J Pharmacol Exp Ther (1979) 0.87
The time course of noradrenergic pre- and postsynaptic activity during chronic desipramine treatment. Eur J Pharmacol (1980) 0.87
Differential effect of benserazide (Ro4-4602) on the concentration of indoleamines in rat pineal and hypothalamus. Br J Pharmacol (1981) 0.86
Clenbuterol, a central beta-adrenoceptor agonist. Acta Pharmacol Toxicol (Copenh) (1980) 0.84
Opposite effects of acute and repeated administration of desmethylimipramine on adrenergic responsiveness in rat pineal gland. Life Sci (1979) 0.81
Neural control of pineal function in mammals and birds. J Neural Transm Suppl (1978) 0.79
Photic input to rat pineal gland conveyed by both sympathetic and central afferents. J Neural Transm (1980) 0.77
Long-term studies on immunoreactive human melatonin. Ann Clin Biochem (1979) 0.77
Selective beta-adrenoceptor antagonism of induced formation of 14C-N-acetylserotonin in rat pineal glands in organ culture. Life Sci (1977) 0.77
Behavioural changes during withdrawal from desmethylimipramine (DMI). I. Interactions with amphetamine. Psychopharmacology (Berl) (1981) 0.77
Behavioural changes during withdrawal from desmethylimipramine (DMI). II. Increased resistance to extinction. Psychopharmacology (Berl) (1981) 0.77
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Cross-cultural primary care: a patient-based approach. Ann Intern Med (1999) 5.06
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
Analysis of vertebrate SCL loci identifies conserved enhancers. Nat Biotechnol (2000) 4.01
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Total synthesis of a human leukocyte interferon gene. Nature (1981) 2.76
Relapse of depression after rapid depletion of tryptophan. Lancet (1997) 2.61
Xwnt-5A: a maternal Wnt that affects morphogenetic movements after overexpression in embryos of Xenopus laevis. Development (1993) 2.58
How to improve plastic surgery knowledge, skills and career interest in undergraduates in one day. J Plast Reconstr Aesthet Surg (2009) 2.54
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
The SCL gene specifies haemangioblast development from early mesoderm. EMBO J (1998) 2.47
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry (2000) 2.25
Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology (2003) 2.14
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol (2008) 2.11
Use of the polymerase chain reaction for the detection of Chlamydia trachomatis from endocervical and urine specimens in an asymptomatic low-prevalence population of women. Diagn Microbiol Infect Dis (1994) 2.09
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol (1972) 2.05
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
BD8 certification of visually impaired people. Br J Ophthalmol (1998) 1.96
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
Human myometrial genes are differentially expressed in labor: a suppression subtractive hybridization study. J Clin Endocrinol Metab (2002) 1.85
Misuse of temazepam. BMJ (1991) 1.82
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
Analysis of pineal and brain indole alkylamines by gas chromatography-mass spectrometry. Adv Biochem Psychopharmacol (1973) 1.71
Direct radioimmunoassay for melatonin in plasma. Clin Chem (1983) 1.69
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development (1999) 1.67
Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion. Neuroimage (1999) 1.65
The SCL gene: from case report to critical hematopoietic regulator. Blood (1999) 1.65
Requirement of Runx1/AML1/PEBP2alphaB for the generation of haematopoietic cells from endothelial cells. Genes Cells (2001) 1.65
Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet (1990) 1.61
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology (2007) 1.57
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
The ethanol stress response and ethanol tolerance of Saccharomyces cerevisiae. J Appl Microbiol (2010) 1.56
Cephalosporin-induced immune neutropenia. Br J Haematol (1985) 1.56
The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berl) (2002) 1.56
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
L-arginine and S-nitrosoglutathione reduce embolization in humans. Circulation (2001) 1.51
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Staphylococcus aureus infections in Australasian neonatal nurseries. Arch Dis Child Fetal Neonatal Ed (2004) 1.49
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Brain 5-HT neurotransmission during paroxetine treatment. Br J Psychiatry (1998) 1.48
Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy. Br J Psychiatry (1992) 1.48
Time to look again at sight tests. BMJ (1997) 1.47
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry (2004) 1.45
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
What proportion of basic surgical trainees continue in a surgical career? A survey of the factors which are important in influencing career decisions. Surgeon (2009) 1.43
A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol (2007) 1.43
Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2011) 1.41
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev Biol (1999) 1.41
The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol Psychiatry (2012) 1.40
Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine. Br J Psychiatry (1997) 1.40
Evaluation of first night effect using ambulatory monitoring and automatic sleep stage analysis. Sleep (1988) 1.39
Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet (1982) 1.39
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development (2001) 1.37
Faecal peritonitis induced by picolax. Br Med J (Clin Res Ed) (1987) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol (1995) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol (2008) 1.34
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke (2009) 1.32
Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL. Proc Natl Acad Sci U S A (1991) 1.32
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology (1985) 1.30
Abnormalities of sleep in patients with the chronic fatigue syndrome. BMJ (1993) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep (1999) 1.28
The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci U S A (1993) 1.28
Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology (Berl) (2003) 1.28
Comparison of the Clearview Chlamydia test, Chlamydiazyme, and cell culture for detection of Chlamydia trachomatis in women with a low prevalence of infection. J Clin Microbiol (1991) 1.27